Knowthestock.com
ADRO - Aduro BioTech, Inc.

Sell

Weak GrowthEarnings/Profit is Negative

25%

based on last 5 year data.
Income Statement is WEAK
Revenue Growth is 64.46%
Operating Income is Negative but improving
Net Income is Negative but improving
Earnings Per Share (EPS) is Negative but improving
Net Margin is -215.8%
Balance Sheet is MODERATE
Current Asset to Current Liability Ratio is 11.27
Debt Ratio is 0.86
Current Debt to Net Income Ratio not available
Total Debt to Total Assets Ratio is 0.0
Cash Flow is WEAK
Cash from Operations is Negative
Capital Expenditure not available
Net Increase in Cash is Positive
Long Term Score Trend is POSITIVE
Investment Risk is High
based on last 4 quarter data.
Unless specified, all values are in USD Millions. Data extracted from SEC Filing and are subject to processing and input errors.
Aduro BioTech, Inc. (ADRO) - http://www.aduro.com
Aduro BioTech, Inc. is a clinical-stage immunotherapy company, which engages in the discovery, development, and commercialization of therapies that transform the treatment of diseases, including cancer. Its technology platforms include STING Pathway Activator, B-select monoclonal antibody, and LADD, or Live, Attenuated, Double-Deleted Listeria monocytogenes. The company's platforms stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies like chemotherapy and radiation as well as other novel immunotherapies. Aduro BioTech was founded in 2000 and is headquartered in Berkeley, CA.
Exchange - NASDAQ
Industry - Biotechnology
Sector - Health Technology
CEO - Stephen T. Isaacs
Employees - 96
    Close


Disclaimer - Investment in securities involves substantial risk and could result in significant loss. It is not suitable for every investor. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser. We may own some of the securities mentioned in this website.
Know the Stock © 2021 and future.